Shandong Sinobioway Biomedicine (002581) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Dark
Light

Open Account

Download

CN Stock MarketDetailed Quotes

002581 Shandong Sinobioway Biomedicine

Watchlist

10.60
-0.04-0.38%

Trading Jan 20 13:06 CST

6.99BMarket Cap-20.11P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) 27% Share Price Plunge Could Signal Some Risk
Simply Wall StJan 3 17:34 ET
Despite Currently Being Unprofitable, Shandong Sinobioway Biomedicine (SZSE:002581) Has Delivered a 88% Return to Shareholders Over 5 Years
Simply Wall StDec 20, 2024 00:02 ET
We're Not Very Worried About Shandong Sinobioway Biomedicine's (SZSE:002581) Cash Burn Rate
Simply Wall StNov 14, 2024 18:12 ET
Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) 43% Share Price Surge Not Quite Adding Up
Simply Wall StOct 8, 2024 19:12 ET
The One-year Earnings Decline Has Likely Contributed ToShandong Sinobioway Biomedicine's (SZSE:002581) Shareholders Losses of 48% Over That Period
Simply Wall StAug 19, 2024 20:28 ET
Some Confidence Is Lacking In Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) P/S
Simply Wall StJun 26, 2024 01:39 ET

Comments

Moomoo AI

Mar 6, 2024 19:05

Shandong Sinobioway Biomedicine's high P/S ratio and slower growth rate may pose a risk to its share price. Overvaluation and continuation of recent revenue trends could negatively impact the share price.

Shandong Sinobioway Biomedicine Co., Ltd. (SZSE:002581) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Moomoo AI

Feb 1, 2024 00:52

Despite the recent sell-off, long-term investors may see this as an opportunity given the company's 13% annual return over five years. It's suggested to check the fundamental data for signs of a long term growth trend.

While Shareholders of Shandong Sinobioway Biomedicine (SZSE:002581) Are in the Black Over 5 Years, Those Who Bought a Week Ago Aren't so Fortunate

Moomoo AI

Dec 24, 2023 18:53

Shandong Sinobioway Biomedicine's high P/S ratio indicates a potential risk of share price decrease. Investors might pay excessive premium if recent medium-term revenue trends persist. The expected business turnaround could lead to disappointment if the P/S ratio aligns more with recent growth rates.